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Hydrogen sulfide (H2S) is a modulator of various physiological and pathological processes inthe cardiovascular and nervous system and plays an important role in the regulation of
gastrointestinal tract, liver and kidney function. The effect of the pleiotropic action of the
tissue specific angiotensin-converting enzyme inhibitor (ACEI), ramipril, exceeds
renin-angiotensin aldosterone system (RAAS) blockade and involves different biological
mechanisms. The aim of the study is to assess the influence of ramipril on H2S production inmouse liver and kidneys. Thirty mice (CBA) of both sexes were given intraperitoneal
injections of ramipril solutions  0.125 mg (5 mg/ kg  group D1) and 0.25 mg (10 mg/ kg 
group D2) for 5 consecutive days at the same time of the day (10:30 am). The control group
received physiological saline in portions of the same volume  0.2 ml. The measurements of
the tissue concentration of H2S were performed using the modified spectrophotometricmethod of Siegel. There was a significant rise in the tissue concentration of H2S [Fg/g] inlivers of group D1 (2.70 ± 0.02 vs 2.81 ± 0.06; P = 0.03) and group D2 (2.70 ± 0.02 vs 2.98 ±
0.03; P <0.001) and a significant decrease of H2S kidney tissue concentration in group D1(3.35 ±0.06 vs 3.15 ± 0.07; P = 0.02) and in group D2 (3.35 ± 0.06 vs 2.89 ± 0.03; P< 0.001).
Our results show that ACEI ramipril affects hydrogen sulfide generation in mouse liver and
kidneys.
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Hydrogen sulfide (H2S) is endogenously pro-
duced in enzymatic reactions in many tissues, es-
pecially in the nervous system, cardiovascular
system, liver and kidney. H2S acts as a gasotrans-
mitter and serves as a modulator of various physio-
logical and pathophysiological processes such as
the regulation of vascular tone, myocardial con-
tractility, neurotransmission, insulin secretion,
biliary bicarbonate excretion, immune and inflam-
matory processes, gastric mucosal integrity, intes-
tinal motility and perception (FIORUCCI et al.
2006; £OWICKA & BE£TOWSKI 2007). The renin-
angiotensin aldosterone system (RAAS) is a hor-
monal cascade that functions in the homeostatic
control of arterial pressure, tissue perfusion, extra-
cellular volume, cell growth end proliferation,
apoptosis, reactive oxygen species generation, in-
flammation and fibrogenesis. Deregulation of the
RAAS plays an important role in the pathogenesis
of cardiovascular and renal disorders and in the pa-
thophysiology of liver diseases (LUBEL et al. 2008;
WOLF 2008). The effects of ramipril – a member
of the angiotensin-converting enzyme inhibitors
(ACEIs) family – exceeds the RAAS blockade.
The pleiotropic action of ACEIs is complex and in-
volves numerous biological systems (ANDERSON
_______________________________________
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et al. 2006; ASSELBERKS & VAN GILST 2006). The
impact of ACEIs on H2S generation in liver and
kidney is unknown. The aim of the study is to as-
sess the influence of ramipril administration on en-
dogenous H2S concentration in mouse liver and
kidney.
Material and Methods
Thirty CBA strain mice of both sexes (3.5-4 months
old individuals) were used in the experiment.*.
The study design comprised intraperitoneal injec-
tions of 0.125 mg (5 mg/ kg – group D1, n = 10)
and 0.25 mg (10 mg/ kg – group D2, n = 10) for 5
consecutive days at the same time of the day
(10:30 am). Ramipril – long acting tissue-specific
non-sulfhydryl ACEI – was dissolved in physio-
logical saline (each administration consisted of 0.2
ml of the solution). The control population (n = 10)
received intraperitoneally physiological saline of
the same volume. The animals tolerated the ap-
plied doses of ramipril well and remained in good
condition till the end of the experiment. Measure-
ments of the H2S concentration were performed by
the use of the modified method of SIEGEL (1965).
Two hours after the last ramipril or physiological
saline injection the animals were killed by cervical
dislocation, their livers and kidneys were quickly
removed and homogenized with 0.01 mol/l so-
dium hydroxide (NaOH) in proportion of 1 to 5.
Then 50% trichloroacetic acid (TCA) was added
(0.5 ml to 2 g of liver samples in tight capsules of 3 ml
and 0.25 ml to 1 g of kidney sample in tight cap-
sules of 2 ml), the suspension was shaken and cen-
trifuged. Subsequently, 1.5 ml liver or 0.75 ml kid-
ney supernatant samples were moved to 2 ml tight
capsules with 0.15 ml or 0.075 ml of 0.02 mol/l
N,N-dimethyl-p-phenyl-diamine sulfate in 7.2 mol/l
hydrochloric acid (HCl), then 0.15 ml or 0.075 ml of
0.03 mol/l iron (III) chloride (FeCl3) in 1.2 mol/l HCl
portions were added, respectively. After 20 minutes
in darkness the content was shaken for 1 minute
with 1 ml of chloroform. Absorbance was meas-
ured at 650 nm with the Varian Cary 100 spectro-
photometer. A standard curve was obtained by
iodometry of a solution of 0.0001 mol/l sodium
sulfide (Na2S) in 0.01 mol/l NaOH. For each group
of animals three concurrent analyses were per-
formed and the average values of the results were
calculated.
Statistical analysis was performed within the R
Environment by the Student’s t-test. Statistical
significance was considered when P<0.05.
Results
The administration of 0.125 mg and 0.25 mg
ramipril (doses D1 and D2 respectively) caused a
statistically significant increase in the liver H2S
tissue concentration by 4.1% and 10.4%, respec-
tively. Conversely, in the kidney ramipril led to the
decrease of H2S tissue concentration in the group
D1 by 6.0% and in D2 by 13.8% (Table 1).
Discussion
Hydrogen sulfide biological action comprises
several intracellular mechanisms and a complex
interaction with carbon monoxide (CO) and nitric
oxide (NO) (£OWICKA & BE£TOWSKI 2007). Sev-
eral digestive system diseases have been associ-
ated with perturbed H2S production. Increased
H2S concentrations were observed in colitis, de-
creased values – in nonsteroidal anti-inflammatory
drugs-induced (NSAID-induced) gastric mucosal
injury and liver cirrhosis (DISTRUTTI et al. 2006;
FIORUCCI et al. 2005a; FIORUCCI et al. 2005b).
Combining data on the roles of RAAS and H2S in
the digestive system comes mainly from research
on chronic liver disorders.
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Table 1
Hydrogen sulfide tissue concentration in mouse liver and kidney following the administra-











Liver H2S tissue concentration
[Fg/g] 2.70 ± 0.02 2.81 ± 0.06 0.03 2.98 ± 0.03 <0.001
Kidney H2S tissue concentration
[Fg/g] 3.35 ± 0.06 3.15 ± 0.07 0.02 2.89 ± 0.03 <0.001
_______________________________________
* The study has been performed in accordance with the guidelines for the care and use of laboratory animals accepted by Bioethi-
cal Committee of the Jagiellonian University Medical College.
Hepatic fibrosis is considered a common re-
sponse to many chronic hepatic injuries. Hepatic
tissue remodelling is highly complex and involves
several cell types, cytokines, chemokines, growth
factors with hepatic stellate cells (HSC) and
RAAS is thought to play an important role in this
process. Angiotensin II (Ang II) promotes activa-
tion and differentiation of HSC into myofibro-
blasts and encourages myofibroblast contraction,
proliferation and promotes the release of inflam-
matory cytokines as well as the deposition of ex-
tracellular matrix (ECM). Along with progressing
fibrosis of the liver, portal hypertension develops,
the main complication of cirrhotic liver. Fixed
changes in hepatic structure account for approxi-
mately 70% of total resistance to portal blood flow
in the cirrhotic liver. The remaining 30% results from
reversible resistance caused by the contraction of
activated myofibroblasts positioned around the si-
nusoidial endothelial cells within the space of Disse
architecture changes. Numerous systems and factors
participate in the control of this resistance, such as
RAAS, the autonomic nervous system, NO, H2S,
endotoxemia,oxidative stress, etc. (LUBEL etal.2008).
H2S regulates perfusion pressure in normal and
cirrhotic liver in a NO-independent manner; NO
and H2S are released by different cellular sources
and their hemodynamic effects involve different
cellular targets. H2S generation in cirrhosis is de-
creased due to the reduced expression/activity of
cystathione ã-lyase (CSE) in HSC – one of the main
sources of H2S in the liver (FIORUCCI et al. 2005).
Numerous studies using a variety of animal
models of chronic liver diseases and results from a
few human trials have demonstrated antifibrotic
effects of RAAS blockade with ACEIs and angio-
tensin receptor blockers (ARBs). Significant re-
ductions in serum markers of hepatic fibrosis such
as transforming growth factor â1 (TGF-â1), type
IV collagen, hyaluronic acid or procollagen III-
N-peptide were observed and signs of lower necro-
inflammatory grade and less advanced stages of fi-
brosis in liver histology were observed in
individuals treated with ACEI or ARB as com-
pared to control groups (JONSSON et al. 2001;
LUBEL et al.2008; RIMOLA et al. 2004; TERUI et
al. 2002; TUNCER et al. 2003). RAAS blockade in-
hibits Ang II – TGF-â1 axis and HSC activation –
one of the key pathologic hepatic fibrosis mecha-
nisms (PEREIRA et al. 2009).
The role of H2S in liver physiology and pathology
and its interplay with RAAS definitely requires
further investigation. Our study provides impor-
tant information that the action of ACEI involves
endogenous H2S generation in liver. We may specu-
late that some of the biological effects of ACEIs
can be mediated by H2S and hydrogen sulfide might
be an important element of the complex regulatory
system of RAAS along with the recently discov-
ered ‘alternative arm of RAAS’ formed by angio-
tensin converting enzyme 2, angiotensin 1-7 and
mas receptor axis (ACE2 – Ang-(1-7) – mas recep-
tor) (LUBEL et al. 2008).
In the kidney cystathione â-synthase (CBS) and
CSE are required to produce H2S. Hydrogen sul-
fide has been recognized as a participant of the
control of renal function which involves both vas-
cular and tubular actions. In the study of XIA et al.
(2009) induction of endogenous H2S production
with L-cysteine (L-Cys) infusion into renal artery
increased glomerular filtration rate (GFR), urine
blood flow, urinary sodium and potassium excre-
tion, fractional excretion of sodium and potassium.
The inhibitory effect of H2S on tubular reabsorp-
tion has been shown to involve Na+/K+/2Cl- co-
transporter (NKCC) and Na+/K+-ATPase (NKA).
Exogenous H2S produced dose-related increases
in renal blood flow, GFR and urinary excretion.
Inhibition of RAAS with ACEIs and ARBs is a
well established part of the treatment of chronic
kidney disorders. These drugs, based on results
from clinical trials including studies with ramipril
such as The Heart Outcomes Prevention Evalua-
tion (HOPE) and Ramipril Efficacy In Nephropathy
(REIN), significantly slow the rate of decline in cre-
atinine clearance and reduce or prevent an increase
in albuminuria and proteinuria with the great clini-
cal benefits of reduced dialysis and renal trans-
plantation rates and a decline in all-cause and
cardiovascular mortality (CHOJNOWSKA-JEZIERSKA
& KOZIRÓG 2005). Kidney RAAS action comprises
interaction with the kinin system and is mediated
by numerous biologically active agents such i.e.
bradykinin, NO, prostaglandins, TGF-â, plasminogen
activator inhibitor-1 (PAI-1) and aldosterone (TAAL
& BRENNER 2000). The kidney H2S effect of GFR
increases with a consequent rise in urinary volume.
Urinary sodium excretion is opposite to Ang II
which among many other cellular targets has a modu-
latory activating action on tubular NKA and NKCC.
The role of H2S in kidney function in normal condi-
tions and in the development of chronic disorders,
especially considering the broad array of H2S bio-
logical mechanisms with its antifibrotic proper-
ties, is a field for future research. As our study has
shown, ramipril decreased concentrations of H2S
in normal mice. The mechanisms of this effect are
yet to be determined as well as the significance of
H2S concentration changes in physiology and pa-
thology of the kidney caused by ACEIs with re-
gards to the complexity of kidney para- and endo-
crine function control. Notably, even the effect of
the RAAS blockade with ACEIs and ARBs on re-
nal hemodynamics has been proven to be quite
variable because of the counteracting influences of
the associated decreases in systemic arterial pres-
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sure and impact of concomitant drugs, including
diuretics or other specific conditions such as re-
stricted sodium intake (KOBORI et al. 2007).
In its biological action ramipril affects H2S
tissue generation. H2S is not only involved in
physiological and pathophysiological processes,
but might also partially account for the effects of
drugs like aspirin, other NSAIDs and ACEIs (FIO-
RUCCI et al. 2007; SREBRO et al. 2006; WILIÑSKI
et al. 2008). This poses another argument for fur-
ther research on the role of H2S in different organs
and systems and future studies on hydrosulfide
(HS) donors and agents releasing H2S in cardio-
vascular medicine, hepatology and nephrology.
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